The dynamic change of neutrophil to lymphocyte ratio can predict clinical outcome in stage I-III colon cancer

Zhigui Li, Rui Zhao, Yaping Cui, Yong Zhou & Xiaoting Wu

Whether the dynamic change of neutrophil to lymphocyte ratio (delta-NLR) can predict the outcome in various malignancies remained controversial. The delta-NLR has not been evaluated in colon cancer. Thus, we conducted the study to evaluate the predictive value of the delta-NLR in patients with colon cancer who underwent curative resection. Three-hundred and fifty-four patients with stage I-III colon cancer were retrospectively analysed. Clinicopathological features, preoperative NLR and postoperative NLR were collected. Prognostic factors were evaluated by univariate and multivariate analysis. The one, three and five-year overall survival rate in the delta-NLR < 0 group was 98.2%, 90.7% and 83.6%, respectively; and in the delta-NLR ≥ 0 group was 98.4%, 96.9% and 95.3%, respectively (log-rank test, \( P = 0.002 \)). Univariate and multivariate analysis showed that there was a strong relationship between delta-NLR and overall survival. In conclusion, the delta-NLR was an independent prognostic factor for overall survival in early stage colon cancer. Patients with increased delta-NLR had a favourable clinical outcome.

Colon cancer remained one of the most common cancer and the leading cause of cancer-related mortality worldwide, with an increased incidence. Previously, the prognosis of patients with colon cancer mainly relied on clinical stage at the time of diagnosis, but which was not entirely reliable. After curative resection which was the only way to cure the disease, approximately 50% of colon cancer patients developed metastatic disease. Even though histological and immunological biomarkers have been widely identified as prognostic factors, these biomarkers were usually inconvenient, time consuming and expensive to measure. Thus, there was no promising predictor of clinical outcome in colon cancer. At present, an active area of study focused on how to distinguish the subset of patients who were at high risk of recurrence and metastasis. It was necessary to explore the predictor of clinical outcome after curative resection.

Recently, the relationship between inflammation and cancer have attracted more and more attention. An increasing body of evidences showed that there was a significant relationship between systemic inflammation and relatively poor survival in various malignancies. Systemic inflammatory responses are thought to take part in tumor progression through inducing angiogenesis and repairing DNA damage, tumor proliferation and metastasis, inhibition of apoptosis, which also caused the changes of haematological components, like neutrophils, lymphocytes, monocytes. Neutrophils, the major components of leukocytes in blood circulation, were considered to be the first line of defense during infections and inflammation. Several studies have shown that neutrophil to lymphocyte ratio (NLR) was an independent factor for progression-free survival (PFS) and overall survival (OS) in various malignancies, including prostate cancer, breast cancer, colorectal cancer, pancreatic cancer. However, previous studies mainly focused on preoperative NLR (pre-NLR) or postoperative NLR (post-NLR). The dynamic change of preoperative and postoperative NLR (delta-NLR) has been rarely studied in colon cancer.

The aim of this study was to evaluate the predictive value of delta-NLR in patients with stage I-III colon cancer who underwent curative resection.
Results
In the present study, a cohort of 968 patients with colorectal cancer were screened. Among them, a total of 616 patients were excluded because of our exclusion criteria. The process of patients selection was shown in Fig. 1. In the end, three-hundred and fifty-four patients with stage I-III colon cancer and complete data were included in this study. Of these, there were 212 males, and 142 females. Age ranged from 18 to 94, with a median age of 62 years. Details about patient’s information were shown in Table 1. The median value of pre-NLR was 2.67 (1.92–3.73) and post-NLR was 2.02 (1.51–2.87). The median (range) follow-up from surgery was 49 (4–69) months. During the follow-up period, 43 (12.1%) were dead at the last follow-up time. The one, three and five-year OS rate of 354 patients was 98.3%, 92.9% and 87.9%, respectively.

In order to evaluate clinical utility of pre-NLR, post-NLR and delta-NLR, receiver operating characteristic (ROC) curves were generated. The area under the ROC curve (AUC) for OS in pre-NLR, post-NLR and delta-NLR was 0.659 (P = 0.001), 0.632 (P = 0.005) and 0.735 (P = 0.000), respectively. The delta-NLR tended to have greater AUC values than pre-NLR and post-NLR (Fig. 2).

We analysed the pre-NLR with the cut-off level of 3\(^\text{th}\). The pre-NLR was decreased in 212 patients (59.9%), and increased in 142 patients (40.1%). When all patients were stratified into two groups by the pre-NLR; the one, three and five-year OS rate in the pre-NLR < 3 group was 99.1%, 97.2% and 92.0%, respectively; and in the pre-NLR ≥ 3...

Figure 1. Diagram showing the process of patients selection.
| Variable               | delta-NLR < 0 (n = 226) | delta-NLR ≥ 0 (n = 128) | P    |
|------------------------|--------------------------|--------------------------|------|
| Age (years)            |                          |                          | 0.392|
| < 60                   | 106                      | 54                       |      |
| ≥ 60                   | 120                      | 74                       |      |
| Gender                 |                          |                          | 0.001|
| Male                   | 150                      | 62                       |      |
| Female                 | 76                       | 66                       |      |
| CEA (U/ml)             | 2.93 (1.63–9.69)         | 3.28 (1.63–8.11)         | 0.993|
| CA199 (U/ml)           | 14.97 (8.18–30.08)       | 13.63 (9.64–31.85)       | 0.982|
| CA125 (U/ml)           | 13.79 (10.41–27.55)      | 12.60 (8.67–19.24)       | 0.016|
| pre-NLR                | 3.05 (2.36–4.54)         | 1.94 (1.37–2.5)          | 0.000|
| post-NLR               | 1.79 (1.38–2.35)         | 2.79 (2.07–3.81)         | 0.000|
| Tumor location         |                          |                          | 0.085|
| Right colon            | 148                      | 72                       |      |
| Left colon             | 78                       | 56                       |      |
| Tumor invasion depth   |                          |                          | 0.000|
| T1 + T2                | 14                       | 30                       |      |
| T3 + T4                | 212                      | 98                       |      |
| Lymph node involvement |                          |                          | 0.058|
| No                     | 160                      | 78                       |      |
| Yes                    | 66                       | 50                       |      |
| Tumor stage            |                          |                          | 0.058|
| I + II                 | 160                      | 78                       |      |
| III                    | 66                       | 50                       |      |
| Tumor grade            |                          |                          | 0.692|
| Low                    | 86                       | 46                       |      |
| Middle, high           | 140                      | 82                       |      |
| Hypertension           |                          |                          | 0.016|
| No                     | 174                      | 112                      |      |
| Yes                    | 52                       | 16                       |      |
| Diabetes mellitus      |                          |                          | 0.091|
| No                     | 204                      | 122                      |      |
| Yes                    | 22                       | 6                        |      |

Table 1. Baseline characteristics of patients with colon cancer. CEA was not indicated for 12 cases; CA-199 was not indicated for 108 cases; CA-125 was not indicated for 118 cases.

Figure 2. Receiver operating characteristic (ROC) curve analysis of the pre-NLR, post-NLR and delta-NLR.
group was 97.2%, 86.6% and 81.7%, respectively (log-rank test, $P = 0.004$). During the follow-up period, 17 (8.0%) were dead in the pre-NLR < 3 group and 26 (18.3%) were dead in the pre-NLR ≥ 3 group (Fig. 3).

We also analysed the post-NLR with the cut-off level of 3. The post-NLR was decreased in 278 patients (78.5%), and increased in 76 patients (21.5%). When all patients were stratified into two groups by the post-NLR; the one, three and five-year OS rate in the post-NLR < 3 group was 98.6%, 92.4% and 86.7%, respectively; and in the post-NLR ≥ 3 group was 97.4%, 94.7% and 92.1%, respectively (log-rank test, $P = 0.196$). During the follow-up period, 37 (13.3%) were dead in the post-NLR < 3 group and 6 (7.9%) were dead in the post-NLR ≥ 3 group (Fig. 4).

We analysed the delta-NLR with the cut-off level of 0$^{17}$. The delta-NLR was decreased in 226 patients (63.8%), and increased in 128 patients (36.2%). When all patients were stratified into two groups by the delta-NLR, the one, three and five-year OS rate in the delta-NLR < 0 group was 98.2%, 90.7% and 83.6%, respectively; and in the delta-NLR ≥ 0 group was 98.4%, 96.9% and 95.3%, respectively (log-rank test, $P = 0.002$). During the follow-up
period, 37 (16.4%) were dead in the delta-NLR < 0 group and 6 (4.7%) were dead in the delta-NLR ≥ 0 group (Fig. 5).

To evaluate the prognosis for clinical outcome in stage I-III colon cancer, potential variables were analysed in univariate and multivariate analysis. Univariate analysis showed that age, differentiation, lymph node involvement, clinical stage, pre-NLR and delta-NLR were significantly associated with OS. Because clinical stage originated from tumor depth, lymph node involvement and distant metastasis, only clinical stage entered the multivariate analysis. Multivariate analysis demonstrated that delta-NLR, pre-NLR, age, differentiation and clinical stage were independent predictors for OS (Table 2).

Discussion
A century ago, Rudolf Virchow firstly found the relationship between inflammation and cancer. In recent decades, a series of studies have demonstrated that systemic inflammatory response was significantly correlated with clinical outcome in various malignancies. NLR was one of the simple and attractive biomarkers for the systemic inflammatory response. Because of low cost and easy accessibility, NLR was widely used in clinical practice.

To the best of our knowledge, only a minority of studies evaluated the prognosis of delta-NLR 17–22. Whether the delta-NLR was an independent prognosis in colon cancer remained unclear. The TNM classification criteria was widely used to predict the prognosis in various malignancies. Patients with stage IV colorectal cancer experienced high morbidity and impaired quality of life; the 5-year OS rate of these patients was approximately 5–15%. Thus, our study excluded stage IV colorectal cancer. A cohort study of 2536 patients conducted by Rashtak et al.23 demonstrated that NLR was no statistically significantly associated with OS and PFS in rectal cancer. For better evaluating the prognosis, we focused on stage I-III colon cancer. In the present study, we evaluated the relationship between the delta-NLR, pre-NLR, post-NLR and clinical outcome in patients with stage I-III colon cancer who underwent curative resection. The present results demonstrated that the delta-NLR was an independent prognostic factor for OS, and delta-NLR ≥ 0 was significantly associated with favourable OS.

Dan et al.19 investigated the relationship between delta-NLR and clinical outcome of small heptocellular carcinomas, and demonstrated that delta-NLR was an independent prognostic factor for OS and PFS. In their study, the survival of patients with increased delta-NLR was significantly poorer than that of decreased delta-NLR. Peng et al.17 also reported that increased delta-NLR predicted worse OS and PFS in small heptocellular carcinomas who underwent curative partial hepatectomy. Jang et al.24 reported that high post-NLR was significantly associated with unfavourable PFS and OS, but there was no relationship between delta-NLR and OS (HR 0.913; 95% CI 0.650–1.283; P = 0.600), PFS (HR 1.162; 95% CI 0.986–1.369; P = 0.074). Ohno et al. studied clear cell renal cell carcinoma and reported that the change of NLR (a combination of the pre-NLR and post-NLR) was an independent predictor for PFS; the 10-year PFS rate in patients with elevated post-NLR was lower than that of decreased post-NLR. Min KW, et al.22 evaluated the relationship between delta-NLR and gastric cancer, and demonstrated that increased delta-NLR was associated with worse outcome. Guo D, et al.21 conducted a retrospective study to evaluate the relationship between delta-NLR and colorectal cancer, which also demonstrated that delta-NLR could predict OS, but could not predict PFS.

The decreased delta-NLR reflected increased pre-NLR and decreased post-NLR. Several recent studies demonstrated that pre-NLR was an independent prognostic factors for clinical outcome in various malignancies. Absenger G, et al. recruited 372 patients with stage II-III colon cancer and found that increased pre-NLR was
Neutrophils affected tumor by means of tumor-associated neutrophils (TANs). Similar to tumor-associated macrophages, TANs exhibited function plasticity, and could be divided into an anti-tumorigenic (N1) phenotype and a pro-tumorigenic (N2) phenotype according to their activation state, cytokine repertoire and effects on tumor growth\(^{27,28}\). N2 TANs have the ability to promote the angiogenesis and tumor proliferation through several biological mechanism. Matrix metalloproteinase-9 (MMP-9) released from N2 TANs could enhance the process of extravasation through degradation of extracellular matrix, reduce apoptosis of tumor cells and increase tumor proliferation\(^{29,30}\). Neutrophil elastase (NE), a serine protease, had the ability to promote proliferation and migration of tumor cells depending on phosphatidylinositol 3-kinase (PI-3K) signal pathway\(^{31,32}\). Cathepsin G released from N2 TANs promoted angiogenesis and migration of tumor cells through upregulating vascular endothelial growth factor (VEGF) and enhancing TGF-β signaling\(^{33}\). Other substances released from N2 TANs, such as reactive oxygen species (ROS), Arginase 1 (ARG1), also contributed to enhance tumor progression. In blood circulation, N2 TANs could induce tumor cell aggregation for helping tumor cells to survive\(^{34}\). Nevertheless, TANs could be modulated and polarized toward N1 phenotype in the presence of type-I interferon or absence of TGF-β\(^{35,36}\). In stark contrast to the pro-tumorigenic function, N1 TANs hindered tumor proliferation and metastasis via producing more superoxide and hydrogen peroxide, promoting CD8+ T cell recruitment and activation, expression of higher levels of Fas, TNF-α and ICAM-1\(^{27,37}\). It was hypothesized that TANs presented pro-tumorigenic function during the preoperative period, TANs presented anti-tumorigenic function during the postoperative period.

Table 2. Univariate and multivariate analysis of prognostic factors for overall survival.

| Variables                  | Univariate analysis | Multivariate analysis (delta-NLR) | Multivariate analysis (pre-NLR) |
|----------------------------|--------------------|-----------------------------------|---------------------------------|
|                            | P value | HR (95%CI) | P value | HR (95%CI) | P value |
| Age(years)                 | <60     | 0.012     | 1       | 0.023     | 1       | 0.013   |
|                           | ≥60     | 2.204 (1.113–4.363) | 2.358 (1.200–4.631) |
| Gender                     | Male    | 0.302     |         |           |         |         |
|                           | Female  |           |         |           |         |         |
| Tumor location             | Right colon | 0.065     | 1       | 0.094     | 1       | 0.060   |
|                           | Left colon | 0.552 (0.276–1.105) | 0.514 (0.257–1.028) |
| Differentiation            | Low     | 0.000     | 1       | 0.000     | 1       | 0.000   |
|                           | Middle, high | 0.284 (0.152–0.530) | 0.324 (0.173–0.606) |
| Tumor invasion depth       | T1 + T2 | 0.114     |         |           |         |         |
|                           | T3 + T4 |           |         |           |         |         |
| Lymph node involvement     | No      | 0.000     |         |           |         |         |
|                           | Yes     |           |         |           |         |         |
| Clinical stage             | I + II  | 0.000     | 1       | 0.000     | 1       | 0.000   |
|                           | III     | 5.101 (2.643–9.845) | 4.771 (2.490–9.141) |
| Delta-NLR                  | <0      | 0.002     | 1       | 0.001     |         |         |
|                           | ≥0      | 0.223 (0.693–0.534) |         |         |         |         |
| Pre-NLR                    | <3      | 0.041     |         |           | 1       | 0.003   |
|                           | ≥3      |           |         |           | 2.524 (1.356–4.698) |
| Post-NLR                   | <3      | 0.196     |         |           |         |         |
|                           | ≥3      |           |         |           |         |         |

significantly associated with worse OS and PFS\(^{25}\). Rashtak S, et al.\(^{23}\) recruited 1622 patients with stage I-III colon cancer and also demonstrated that pre-NLR was significantly associated with worse OS and PFS. Similar to other studies, our study also confirmed that increased pre-NLR correlated with unfavourable outcome in patients with colon cancer. Several studies investigated the relationship between post-NLR and clinical outcome. Miyatani K, et al. reported that decreased post-NLR was significantly associated with better clinical outcome in gastric cancer\(^{26}\). Ohno Y, et al. reported that decreased post-NLR was a significant prognostic factor for better PFS in patients with clear cell renal cell carcinoma\(^{20}\). Our study demonstrated that increased post-NLR was slightly associated with better clinical outcome. Compared with preoperative or postoperative NLR, delta-NLR could be considered as an accurate reflection of host immune response.

Our results of delta-NLR and post-NLR were inconsistent with them. There were several reasons for this contradiction. First, Dan et al. and Peng et al. studied small heptocellular carcinomas, Jang et al. studied localized prostate cancer, Ohno et al. studied clear cell renal cell carcinoma, Min et al. studied gastric cancer, we studied stage I-III colon cancer. It was not ruled out the possibility that the prognosis of delta-NLR in various malignancies was diverse. Second, except the study conducted by Jang et al.\(^{24}\), the rest of sample size was relatively small and the amount of other included patients was less than three hundred.

Until now, the underlying mechanism responsible for increased delta-NLR and long-term survival in colon cancer remained poorly understood. Several biological mechanism could contribute to the relationship. It was well known that delta-NLR was influenced by pre-NLR and post-NLR, reflecting the balance between systemic inflammatory response and immune response. An increased NLR revealed a relatively neutrophilia and lymphocytopenia. Lymphocytes inhibited the tumor proliferation and metastasis through enhancing cytotoxic cell death and cytokine production. Relative lymphocytopenia could suppress anti-tumorigenic immune response\(^{12}\). Neutrophils affected tumor by means of tumor-associated neutrophils (TANs). Similar to tumor-associated macrophages, TANs exhibited function plasticity, and could be divided into an anti-tumorigenic (N1) phenotype and a pro-tumorigenic (N2) phenotype according to their activation state, cytokine repertoire and effects on tumor growth\(^{27,28}\). N2 TANs have the ability to promote the angiogenesis and tumor proliferation through several biological mechanism. Matrix metalloproteinase-9 (MMP-9) released from N2 TANs could enhance the process of extravasation through degradation of extracellular matrix, reduce apoptosis of tumor cells and increase tumor proliferation\(^{29,30}\). Neutrophil elastase (NE), a serine protease, had the ability to promote proliferation and migration of tumor cells depending on phosphatidylinositol 3-kinase (PI-3K) signal pathway\(^{31,32}\). Cathepsin G released from N2 TANs promoted angiogenesis and migration of tumor cells through upregulating vascular endothelial growth factor (VEGF) and enhancing TGF-β signaling\(^{33}\). Other substances released from N2 TANs, such as reactive oxygen species (ROS), Arginase 1 (ARG1), also contributed to enhance tumor progression. In blood circulation, N2 TANs could induce tumor cell aggregation for helping tumor cells to survive\(^{34}\). Nevertheless, TANs could be modulated and polarized toward N1 phenotype in the presence of type-I interferon or absence of TGF-β\(^{35,36}\). In stark contrast to the pro-tumorigenic function, N1 TANs hindered tumor proliferation and metastasis via producing more superoxide and hydrogen peroxide, promoting CD8+ T cell recruitment and activation, expression of higher levels of Fas, TNF-α and ICAM-1\(^{27,37}\). It was hypothesized that TANs presented pro-tumorigenic function during the preoperative period, TANs presented anti-tumorigenic function during the postoperative period.
Our study demonstrated that increased post-NLR was associated with better clinical outcome and increased pre-NLR was associated with unfavorable clinical outcome, which supported above hypothesis.

It was noted that there were several limitations in the present study. First, this was a retrospective study at a single institution, so the results may not be generalizable. Second, the weakness of small sample size and relative short follow-up period could not be neglected. Third, data of adjuvant chemotheraphy were not routinely available in this analysis.

In conclusion, irrespective of the limitations mentioned above, our study showed that the delta-NLR was an independent prognostic factor for patients with early stage colon cancer who underwent curative resection, and increased delta-NLR was significantly associated with better OS. Further large-scale and well designed prospective studies are still needed to confirm the present results.

Materials and Methods

Study population. Patients with colon cancer in our study were recruited between February 2012 and March 2015 from the Department of gastrointestinal surgery, West China Hospital. All participants signed the informed consents. The study adhered to the principles of the Declaration of Helsinki, and was approved by the Ethics Committee of West China Hospital of Sichuan University. All patients with colon cancer underwent curative resection and were confirmed by a postoperative pathologic examination.

In the present study, the inclusion criteria were as follows: (1) age 19–94 years; (2) stage T1–4, N0–2, M0; (3) no preoperative antitumor treatment, such as radiotherapy, chemotherapy; (4) survival time beyond 3 months; (5) adequate bone marrow function (absolute neutrophil count no less than 1.5 \times 10^9/L); (6) patient with preoperative and postoperative blood routine tests.

Exclusion criteria included the following: (1) clinical history with hemopathy or synchronous malignancy; (2) with metastasis; (3) recurrent colon cancer; (4) multifocal lesions; (5) loss to follow-up within 3 months after surgery. In the light of our inclusion and exclusion criteria, a total of 354 patients with pre-NLR and post-NLR data were enrolled in this study.

Patients characteristics. Clinical characteristics including age, gender, tumor location, medical history, carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA-199), carbohydrate antigen 125 (CA-125) and pathological features were obtained through a retrieval of our prospectively maintained database. Clinical stage was determined according to the 7th edition of the American Joint Committee on Cancer (AJCC) staging system.

Peripheral blood parameters. Preoperative blood routine test was obtained within one week before curative resection; postoperative blood routine test was taken during the recovery period of one to three months after surgery. Leukocyte, neutrophil and lymphocyte were collected from the blood routine test. The normal range of leukocyte count was from 4 \times 10^9/L to 10 \times 10^9/L. The NLR (a single value for each patient) was calculated as the absolute neutrophil count divided by the absolute lymphocyte count. The delta-NLR was defined as post-NLR minus pre-NLR.

Follow-up visit. All patients were suggested to return for a follow-up visit at the first month after surgery, every 3 months during the following 3 years, and every 6 months in the subsequent years. The follow-up period was defined as the duration of time from the date of surgery to the date of the last known contact or the date of death. OS was calculated from the date of surgery to the date of death by any causes. The last follow-up date was the end of December 2017.

Statistical analysis. We performed the ROC curve analysis to count the AUC and then determine the optimal prognosis. Normally distributed data were presented as mean \pm standard deviation and abnormally distributed data as median (quartile range). We compared categorical data by the chi-square test. The univariate analysis was performed by the Kaplan–Meier method with a log-rank test. Potential effects of clinicopathological variables on OS were firstly examined using univariate analysis. Multivariate Cox-regression analysis was used to further assess the variables which was proved significant in univariate analysis. Hazard ratio (HR) and 95% confidence interval (CI) estimated from the Cox analysis were reported. All statistical analyses were performed using SPSS 19.0 software (SPSS, Inc., Chicago, IL, USA), and two-sided P value of less than 0.05 was considered statistically significant.

References
1. Torre, L. A. et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians 65, 87–108 (2015).
2. Center, M. M., Jemal, A. & Ward, E. International trends in colorectal cancer incidence rates. Cancer epidemiology, biomarkers & prevention 18, 1688–1694 (2009).
3. Pan, P., Yu, J. & Wang, L. S. Colon Cancer: What We Eat. Surgical oncology clinics of North America 27, 243–267 (2018).
4. Crozier, J. E. et al. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. British journal of cancer 94, 1833–1836 (2006).
5. Scott, H. R. et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. British journal of cancer 87, 264–267 (2002).
6. Roxburgh, C. S. & McMillan, D. C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future oncology 6, 149–163 (2010).
7. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).
8. Hainaut, P. & Plymoth, A. Targeting the hallmarksof cancer: towards a rational approach to next-generation cancer therapy. Current opinion in oncology 25, 50–51 (2013).
9. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
10. Jaiswal, M., LaRusso, N. F., Burgart, L. J. & Gores, G. J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer research 60, 184–190 (2000).
11. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. *Nature* **454**, 436–444 (2008).
12. Langsenlehner, T. et al. Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. *World journal of urology* **33**, 1661–1667 (2015).
13. Ethier, J. L., Desautels, D., Templeton, A., Shah, P. S. & Amir, E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. *Breast cancer research: BCR* **19**, 2 (2017).
14. Pedrazzini, C. et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. *Scientific reports* **7**, 1494 (2017).
15. Yang, J. J. et al. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. *World journal of gastroenterology* **21**, 2807–2815 (2015).
16. Lee, S. et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. *BMC cancer* **13**, 350 (2013).
17. Peng, W. et al. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. *The Journal of surgical research* **192**, 402–408 (2014).
18. Chen, T. M., Lin, C. C., Huang, P. T. & Wen, C. F. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. *Journal of gastroenterology and hepatology* **27**, 533–561 (2012).
19. Dan, J. et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. *PloS One* **8**, e58184 (2013).
20. Ohno, Y. et al. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. *The Journal of urology* **187**, 411–417 (2012).
21. Guo, D. et al. Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients. *Future oncology* (2018).
22. Min, K. W. et al. Persistent elevation of postoperative neutrophil-to-lymphocyte ratio: A better predictor of survival in gastric cancer than elevated preoperative neutrophil-to-lymphocyte ratio. *Scientific reports* **7**, 13967 (2017).
23. Rashat, S. et al. Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer. *Clinical colorectal cancer* **16**, 115–123 e113 (2017).
24. Jang, W. S. et al. The prognostic significance of postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for localized prostate cancer. *Oncotarget* **8**, 11778–11787 (2017).
25. Absenger, G. et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. *British journal of cancer* **109**, 395–400 (2013).
26. Miyatani, K. et al. Combined analysis of the pre- and postoperative neutrophil-to-lymphocyte ratio predicts the outcomes of patients with gastric cancer. *Surgery today* **48**, 300–307 (2018).
27. Fridlender, Z. G. et al. Polarization of Tumor-Associated Neutrophil Phenotype by TGFBeta: “N1” versus “N2” TAN. *Cancer cell* **16**, 183–194 (2009).
28. Sionov, R. V., Fridlender, Z. G. & Granot, Z. The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. *Cancer microenvironment* **8**, 125–158 (2015).
29. Coussens, L. M., Trinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. *Cell* **103**, 481–490 (2000).
30. Aucell, H. B., Carter, K. J., Fingleton, B., Gordon, D. L. & Matrisian, L. M. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. *Cancer research* **66**, 259–266 (2006).
31. Gaído, M. M. et al. Polymorphonuclear neutrophils promote dysheesion of tumor cells and elastase-mediated degradation of E-cadherin in pancreatic tumors. *European journal of immunology* **42**, 3369–3380 (2012).
32. Houghton, A. M. et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. *Nature medicine* **16**, 219–223 (2010).
33. Yui, S., Osawa, Y., Ichisugi, T. & Morimoto-Kamata, R. Neutrophil cathepsin G, but not elastase, induces aggregation of MCF-7 mammary carcinoma cells by a protease activity-dependent cell-oriented mechanism. *Mediators of inflammation* **2014**, 971409 (2014).
34. Morimoto-Kamata, R., Mizuguchi, S., Ichisugi, T. & Yui, S. Cathepsin G induces cell aggregation of human breast cancer MCF-7 cells via a 2-step mechanism: catalytic site-independent binding to the cell surface and enzymatic activity-dependent induction of the cell aggregation. *Mediators of inflammation* **2012**, 456462 (2012).
35. Andzinski, L. et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. *International journal of cancer* **138**, 1982–1993 (2016).
36. Granot, Z. & Jablonska, J. Distinct Functions of Neutrophil in Cancer and Its Regulation. *Mediators of inflammation* **2015**, 701067 (2015).
37. Fridlender, Z. G. & Albelda, S. M. Tumor-associated neutrophils: friend or foe? *Carcinogenesis* **33**, 949–955 (2012).
38. Hari, D. M. et al. AJCC Cancer Staging Manual7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? *Journal of the American College of Surgeons* **217**, 181–190 (2013).

**Author Contributions**
Z.G.L. designed the study and wrote this manuscript. Z.G.L., Y.P.C. and R.Z. retrieved database. Y.Z. and X.T.W. interpreted the data and proofread the final version. All of the authors have read and approved the final manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018